跳至主要内容
临床试验/ISRCTN62041885
ISRCTN62041885已完成未知

The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on response to vaccines among rural Ugandan adolescents

ondon School of Hygiene and Tropical Medicine0 个研究点目标入组 341 人开始时间: 2019年8月23日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
341

研究概览

简要总结

2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33593769/ (added 16/08/2022) 2021 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33593767/ (added 03/05/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Attending the selected school and planning to continue to attend the school for the duration of the study
  • 2. Aged 9 to 17 years and enrolled in primary 1 to 6
  • 3. Written informed assent by participant and consent by parent or guardian
  • 4. Agree to avoid pregnancy for the duration of the trial (female only)
  • 5. Willing to provide locator information and to be contacted during the course of the trial
  • 6. Able and willing (in the investigator’s opinion) to comply with all the study requirements

排除标准

  • 1. Clinically significant history of immunodeficiency (including HIV), cancer, cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illnesses.
  • 2. Moderate or severe acute illness characterised any of the following symptoms: fever, impaired consciousness, convulsions, difficulty in breathing, vomiting; or as determined by the attending project clinician.
  • 3. Family history of sudden death attributable to a heart condition in a first-degree relative
  • 4. Family history of long QT syndrome
  • 5. Know congenital prolongation of the QTc interval
  • 6. History of known heart disease or fainting
  • 7. Known allergy or history of adverse reaction to DP or to artemether-lumefantrine
  • 8. History of serious psychiatric condition or disorder
  • 9. Previous immunisation with Yellow Fever (YF), oral typhoid or Human Papillomavirus (HPV) vaccine; previous immunisation with BCG or Tetanus and diphtheria vaccine (Td) at age >5 years
  • 10. Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents within 2 months prior to enrolment
  • 11. Current use of medications known to prolong the QT interval (Table 2)
  • 12. History of an allergic reaction to immunisation or any allergy likely to be exacerbated by any component of the study vaccines including egg or chicken proteins
  • 13. Tendency to develop keloid scars
  • 14. Haemoglobin less than 80g/L
  • 15. Positive HIV serology
  • 16. Positive pregnancy test
  • 17. Female currently lactating, confirmed pregnancy or intention to become pregnant during the trial period
  • 18. Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the study vaccines for 30 days prior to dosing with the study vaccine, or planned use during the study period
  • 19. Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial immunisation date.

研究者

发起方
ondon School of Hygiene and Tropical Medicine

相似试验